Serelaxin, a 'Breakthrough' investigational intravenous agent for acute heart failure

P and T

Volumn 38, Issue 10, 2013, Pages 606-611

  Miyares, Marta A ^a   Davis, Kyle A ^b  

^a JACKSON MEMORIAL HOSPITAL   (United States)

^b Caspi and Associates in New York   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN B RECEPTOR; FUROSEMIDE; G PROTEIN COUPLED RECEPTOR; NITRIC OXIDE; PLACEBO; SERELAXIN; VASCULOTROPIN;

ACUTE HEART FAILURE; ANGINA PECTORIS; ARTICLE; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELECTROLYTE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HEMODYNAMIC PARAMETERS; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY BLOOD FLOW; KIDNEY FAILURE; LIVER FUNCTION TEST; MORTALITY; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; VASODILATATION; VISUAL ANALOG SCALE; VITAL SIGN;

EID: 84885820563     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA Task Force Members. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, June 5, 2013 (online).
2. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137-1146.
3. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation 2011; 123(8):933-944.
4. Laribi S, Aouba A, Nikolaou M, et al. Trends in death attributed to heart failure over the past two decades in Europe. Eur J Heart Fail 2012;14:234-239.
5. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur J Heart Fail 2012;14(8):803-869; erratum, Eur J Heart Fail 2013;15(3):361-362.
6. Allen LA, O'Connor CM. Management of acute decompensated heart failure. Can Med Assoc J 2007;176 (6):797-805.
7. Felker GM, Lee KL, Bull DA, et al. NHLBI [National Heart, Lung, and Blood Institute) Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364(9):797-805.
8. Mebazaa A, Pang PS, Tavares M, et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: The URGENT-dyspnoea study. Eur Heart J 2010;31: 832-841.
9. Metra M, O'Connor CM, Davison BA, et al. Early dyspnoea relief in acute heart failure: Prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. Eur Heart J 2011;32:1519-1534.
10. Metra M, Teerlink JR, Felker GM, et al. Dyspnoea and worsening heart failure in patients with acute heart failure: Results from the Pre-RELAX-AHF study. Eur J Heart Fail 2010;12:1130-1139.
11. Hernandez-Montfort JA, Arora S, Slawsky MT. Relaxin for treatment of acute heart failure: Making the case for treating targeted patient profiles. Curr Heart Fail Rep 2013;10(3):198-203.
12. Metra M, Teerlink JR, Voors AA, et al. Vasodilators in the treatment of acute heart failure: What we know, what we don't. Heart Fail Rev 2009;14(4):299-307.
13. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365(1):32-43.
14. Cuffe MS, Califf RM, Adams KF Jr, et al. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. JAMA 2002;287(12):1541-1547.
15. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009;53:557-573.
16. Cotter G, Metra M, Milo-Cotter O, et al. Fluid overload in acute heart failure: Redistribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008;10:165-169.
17. Conrad KP. Maternal vasodilation in pregnancy: The emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol 2011;301:R267-R275.
18. Dschietzig T, Teichman S, Unemori E, et al. Intravenous recombinant human relaxin in compensated heart failure: A safety, tolerability, and pharmacodynamic trial. J Card Fail 2009;15:182-190.
19. Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M. Relaxin: Review of biology and potential role in treating heart failure. Curr Heart Fail Rep 2010;7:75-82.
20. Teerlink JR, Cotter G, Davison BA, et al; RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAXAHF): A randomised, placebo-controlled trial. Lancet 2013;381(9860):29-39.
21. Dschietzig T, Teichman S, Unemori E, et al. First clinical experience with intravenous recombinant human relaxin in compensated heart failure. Ann NY Acad Sci 2009;1160:387-392.
22. Teichman SL, Unemori E, Dschietzig T, et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev 2009;14(4):321-329.
23. Gavino ES, Furst DE. Recombinant relaxin: A review of pharmacology and potential therapeutic use. BioDrugs 2001; 15(9):609-614.
24. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): A multicentre, randomised, placebocontrolled, parallel-group, dose-finding phase IIb study. Lancet 2009;373(9673): 1429-1439.
25. Ponikowski P, Metra M, Teerlink JR, et al. Design of the RELAXin in acute heart failure study. Am Heart J 2012;163(2):149-55. e1.